Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1
HIV Infections
Acquired Immunodeficiency Syndrome

Interventions

DRUG: E/C/F/TAF
DRUG: DRV
DRUG: Baseline DRV- containing ARV regimen

Sponsor

Gilead Sciences